Search

The article presents a case study of eight patients who developed pulmonary injury during administration with carmustine and cyclophosphamide, for lymphoma in six patients and leukaemia in two patients.

The article presents a case study of a 21-year-old woman who experienced cytomegalovirus (CMV) reactivation after receiving myeloablative conditioning therapy with antithymocyte-globulin, carmustine, fludarabine and melphalan for acute myeloid leukemia.

The article presents a case study of a patient who developed pneumonitis after receiving carmustine for the treatment of refractory Hodgkin lymphoma.

The article presents a case study of a 57-year old man who developed vasospasm after undergoing tumor resection and implantation of eight carmustine wafers inside the resection cavity for glioblastoma.

The article presents a case study of a patient who developed cerebral reactive cyst during the administration of carmustine polifeprosan.

The article presents a case study of a patient who died secondary to drug toxicity following treatment with carmustine, cytarabine, and etoposide.

The article presents ten case studies involving six males and four females aged 0.3 year to 10.7 years who developed several complications including vomiting, diarrhoea and pneumonia during treatments including carmustine, cytarabine and etoposide.

The article presents a case study of a 51-year-old man who developed fatal relapse of acute myeloid leukaemia while receiving antineoplastics, including carmustine, cyclophosphamide, and etoposide.

The article presents two case studies of patients who developed telangiectases post administration of carmustine.

The article presents case studies of as a 43-year-old woman, suffering from secondary glioblastoma, and a 76-year-old woman, diagnosed with glioblastoma, who developed delayed cerebral edema while receiving treatment with carmustine.

This section offers news briefs related to pharmacovigilance and drug laws. Bristol-Myers Squibb (BMS) is recalling 10 lots of BiCNU (carmustine for injection) with expiration dates from November 2012 through April 2012. About 360 reports of liver injury associated with the use of non-tuberculosis antibiotics was received by the Centre for Adverse Reactions Monitoring, New Zealand. A study found that there is no association between statin use and new-onset type 2 diabetes mellitus (T2DM).

The article presents a case study of two patients in which patient one developed cerebrospinal fluid leak while another patient developed methicillin resistant Staphylococcus aureus surgical site infection following treatment with intracerebral carmustine polifeprosan-20 wafer.

An abstract of the article "Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas" by Z. Gokce-Samar and others is presented.

The article describes cases of febrile neutropenia and thrombocytopenia in one patient during treatment with ibritumomab tiuxetan-y-90, carmustine, etoposide, cytarabine and melphalan, and neutropenia and thrombocytopenia in four patients during treatment with ibritumomab tiuxetan-y-90 (zevalin).

The article describes the case of patients who developed various toxicities including cerebral oedema, pyrexia and wound healing failure after the implantation of carmustine polifeprosan-20 wafer for malignant glioma.

The article describes the case of chronic phase intracranial haemorrhage cuased by ruptured pseudoaneurysm that developed in a 42-year-old man following treatment with carmustine.

The article presents case report of a patient who developed cyst, inflammatory reaction and convulsive attacks after the implantation of carmustine polifeprosan-20 wafer.

The article presents case studies of eight patients aged 50-72 years old who were diagnosed with post-operative haemorrhage following high-grade glioma surgery and insertion of carmustine wafers.

The article presents case reports of a 55-year-old woman and a 57-year-old man who developed haematotoxicity while receiving carmustine.

The article presents case studies of a 43-year-old man with left temporal glioblastoma and a 47-year old woman with left frontal anaplastic oligodendroglioma who both developed ischaemic stroke following treatment of carmustine polifeprosan 20 wafer.

The article presents a case study of a 46-year-old man who developed acute coronary syndrome for taking carmustine for central nervous system (CNS) lymphoma.

The article presents a case study of a 53-year old woman, who suffered from an undifferentiated sarcoma while being treated with carmustine [BCNU] as chemotherapy for glioblastoma multiforme.

The article describes the case of a 70-year-old woman who developed pneumonitis and subsequently died after receiving carmustine, cyclophosphamide and etoposide.